Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

TaiMed Biologics

Request full access

Offers Ibalizumab, a monoclonal antibody and a member of HIV viral-entry inhibitor therapy

Taipei, TaiwanFounded 2007Biotech & Life Sciences

About TaiMed Biologics

Established in 2007, TaiMed Biologics Inc. operates as a clinical-stage biopharmaceutical company with a strategic focus on the research and development of treatments for infectious diseases, particularly HIV/AIDS. The company's inception traces back to a team of prominent scientists and industry veterans, including Dr. David Ho and Dr. Tse-Wen Chang, who brought extensive experience in virology and immunology. Dr. Ho, a notable Taiwanese-American AIDS researcher, and Dr. Chang, a distinguished immunologist recognized for his work on an anti-IgE antibody that led to the development of Xolair, provided a strong scientific foundation for the company. The establishment of TaiMed was significantly supported by the Taiwanese government's National Development Fund, which was the largest shareholder upon its founding, underscoring a national strategic interest in building a global biotechnology firm.

TaiMed's primary business revolves around developing proprietary monoclonal antibodies (mAbs) to address unmet medical needs. Its flagship product, Trogarzo® (ibalizumab), represents a significant milestone as the first long-acting monoclonal antibody and the first new mechanism of action for HIV treatment in over a decade. Trogarzo® is a humanized monoclonal antibody that functions as a post-attachment HIV-1 inhibitor, binding to the CD4 receptor on host T-cells and blocking the virus from entering. This mechanism is particularly crucial for patients with multi-drug resistant HIV who have limited treatment options remaining. The product is administered intravenously every two weeks, offering a less frequent dosing schedule compared to daily oral antiretrovirals.

The company's business model encompasses both proprietary drug development and Contract Development and Manufacturing Organization (CDMO) services. Revenue is generated through the commercialization of its products, like Trogarzo®, which is marketed in the United States by Theratechnologies. Furthermore, TaiMed leverages its advanced manufacturing facilities and expertise in monoclonal antibodies to offer development and production services to other biopharmaceutical companies, guiding their products from the clinical development stage to market launch. The company's client base includes patients with multi-drug resistant HIV and other biopharmaceutical firms seeking specialized CDMO support. TaiMed operates in the global biopharmaceutical market, with a significant presence in North America and Europe through its partnerships and product approvals.

Source: Dealroom company data

At a glance

Status
Operational
Employees
49
Open positions
None listed
Dealroom signal
75.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Infections and Infectious Diseases, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2010 $22M $88M YFY Biotech Management Company —
SPINOUT✓Other financing Sep 2007 $0 — Rockefeller University · Columbia University Irving Medical Center —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

TaiMed Biologics website traffic

Latest recorded traffic for TaiMed Biologics is 2.7K monthly website visits, down 6.9% over the last three months. TaiMed Biologics's team grew 8.9% over the past year.

Latest monthly visits2.7K 3-month web change-6.9% 1-year team growth+8.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

TaiMed Biologics in the Taipei ecosystem

Live from Dealroom

The TaiMed Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • YFY Biotech Management Company

Other known investors2 additional known investors

  • Columbia University Irving Medical Center
  • Rockefeller University
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇹🇼 Taiwan76.7%
🇺🇸 United States3.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about TaiMed Biologics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See TaiMed Biologics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.